CDTX vs AGIO

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). Analysts rate Cidara Therapeutics, Inc. (CDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cidara Therapeutics, Inc.

(CDTX) delivered a total return of +448. 0%, compared to -48. 9% for Agios Pharmaceuticals, Inc. (AGIO). Over 10 years, the gap is even starker: CDTX returned -14. 7% versus AGIO's -36. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.

(CDTX) is the lower-risk stock at 0. 87β versus Agios Pharmaceuticals, Inc. 's 1. 12β — meaning AGIO is approximately 29% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 5% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). On earnings-per-share growth, the picture is similar: Agios Pharmaceuticals, Inc. grew EPS -161. 2% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agios Pharmaceuticals, Inc.

(AGIO) is the more profitable company, earning -764. 0% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps -764. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGIO leads at -873. 9% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cidara Therapeutics, Inc.

(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (CDTX: -14. 7%, AGIO: -36. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CDTX is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.